Emerging treatments for inflammatory bowel disease

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

(2019) William J. Sandborn et al.   GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease

(2018) Julián Panés et al.   GASTROENTEROLOGY

OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study

(2018) S Danese et al.   Journal of Crohns & Colitis

The role of diet in the aetiopathogenesis of inflammatory bowel disease

(2018) Hamed Khalili et al.   Nature Reviews Gastroenterology & Hepatology

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis

(2018) William J. Sandborn et al.   GASTROENTEROLOGY

Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease

(2017) Allan B. Dietz et al.   GASTROENTEROLOGY

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

(2017) Yoram Bouhnik et al.   GUT

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn’s Disease: Efficacy in a Single-Centre Cohort

(2017) Alicia López-García et al.   Journal of Crohns & Colitis

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses

(2016) T. Dhere et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines

(2016) Silvio Danese et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Investigating cell therapy for inflammatory bowel disease

(2016) Ryuichi Okamoto et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Next generation of small molecules in inflammatory bowel disease

(2016) Pablo Olivera et al.   GUT

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial

(2016) M. Scott Harris et al.   Journal of Crohns & Colitis

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes

(2016) Gionata Fiorino et al.   Therapeutic Advances in Gastroenterology

Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease

(2015) P. Luthra et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

(2015) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

(2015) Paul Moayyedi et al.   GASTROENTEROLOGY

Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus

(2015) Brian Bressler et al.   GASTROENTEROLOGY

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy

(2015) Richard L. Proia et al.   JOURNAL OF CLINICAL INVESTIGATION

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

(2015) Sanjaya Singh et al.   mAbs

Sa1207 Pharmacokinetics/Pharmacodynamics (PK/PD), Efficacy, and Safety of AMG 181 in Subjects With Active, Mild to Moderate Ulcerative Colitis - An Initial Assessment

(2015) Wei-Jian Pan et al.   GASTROENTEROLOGY

Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients

(2014) Colleen R Kelly et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biological Agents for Moderately to Severely Active Ulcerative Colitis

(2014) Silvio Danese et al.   ANNALS OF INTERNAL MEDICINE

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis

(2014) Ruben J. Colman et al.   Journal of Crohns & Colitis

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Transient Flare of Ulcerative Colitis After Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

(2013) Lauren M. De Leon et al.   Clinical Gastroenterology and Hepatology

Etrolizumab: Anti-β7—A Novel Therapy for Ulcerative Colitis

(2013) Kirk K. Lin et al.   GASTROENTEROLOGY

Induced and Natural Regulatory T Cells in the Development of Inflammatory Bowel Disease

(2013) Christopher G. Mayne et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease

(2013) Mehmet Coskun et al.   PHARMACOLOGICAL RESEARCH

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Discovery and mechanism of ustekinumab

(2012) Jacqueline M. Benson et al.   mAbs

Fingolimod for Multiple Sclerosis

(2012) Daniel Pelletier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammatory Bowel Disease of the Elderly: Frequently Asked Questions (FAQs)

(2011) Seymour Katz et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

(2011) EG Stefanich et al.   BRITISH JOURNAL OF PHARMACOLOGY

Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease

(2011) Jun Liang et al.   GUT

Intestinal homeostasis and its breakdown in inflammatory bowel disease

(2011) Kevin J. Maloy et al.   NATURE

Hematopoietic Stem Cell Homing to Injured Tissues

(2011) Dean Philip John Kavanagh et al.   Stem Cell Reviews and Reports

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study

(2010) Marjolijn Duijvestein et al.   GUT

Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody

(2009) N Pullen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

The Role of Stromal Stem Cells in Tissue Regeneration and Wound Repair

(2009) T. S. Stappenbeck et al.   SCIENCE